Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice ; volume:16 ; number:1 ; day:16 ; month:2 ; year:2016 ; pages:1-9 ; date:12.2016
BMC cancer ; 16, Heft 1 (16.2.2016), 1-9, 12.2016
- Urheber
-
Razenberg, L. G. E. M.
- Beteiligte Personen und Organisationen
-
van Gestel, Y. R. B. M.
de Hingh, I. H. J. T.
Loosveld, O. J. L.
Vreugdenhil, G.
Beerepoot, L. V.
Creemers, G. J.
Lemmens, V. E. P. P.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2158-8
- URN
-
urn:nbn:de:1111-2016072639949
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Razenberg, L. G. E. M.
- van Gestel, Y. R. B. M.
- de Hingh, I. H. J. T.
- Loosveld, O. J. L.
- Vreugdenhil, G.
- Beerepoot, L. V.
- Creemers, G. J.
- Lemmens, V. E. P. P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer